Dr. Hua Zhu (David) Ke
? Founder and CEO, Angitia Biopharmaceuticals, Guangzhou, China and Alhambra, California, USA
Other Academic Affiliation:
? Adjunct Professor, Department of Radiology, Division of Radiobiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
? Adjunct Professor, Department of Orthopaedics and Traumatology, Chinese University of Hong Kong, Hong Kong, China
? Visiting Professor, Guangdong Medical College, Zhanjiang, Guangdong, China
David Ke’s research interests include bone biology, osteoporosis, fracture healing, muscle frailty and kidney diseases. David has been involving and leading the drug discovery research and development in estrogen receptor modulator (lasofoxifene), EP2 and EP4 receptor agonists, RANKL antibody (denosumab, approved for human use in 2010, with annual sales of 2018 greater than $4 billion USD) and sclerostin antibody (romosozumab, approved in Japan on Jan 8,2019 for approval in human osteoporosis, and a 18 to 1 voted in an US FDA Advisory Committee recommend for approval on Jan 16, 2019)) at Pfizer, Groton, Connecticut, USA (1992 – 2005, from Senior Research Scientist to Research Fellow), Amgen, Thousand Oaks, California, USA (2005 – 2014, from Scientific Director to Scientific Executive Director and Head of Bone and Mineral Research) and UCB Pharma, Slough, United Kingdom (2015 – 2018, Vice President and Head of Bone Therapeutic Area).
David resigned from his position of Vice President and Head of Bone Therapeutic Area at UCB Pharma in June 2018, and then established Angitia Biopharmaceuticals, a global biotechnology company focusing on the discovery and development of innovative therapeutics for grievous musculoskeletal diseases. At the same time, he is contributing to the establishment of Joint Center for Musculoskeletal Research, Guangzhou Regenerative Medicine Guangdong Laboratory.
David has published 148 peer-review scientific publications and invited reviews, with more than 9500 citation and H-index of 49, and is the inventor of 26 patents. He and his group has delivered more than 250 scientific presentations in the forms of international scientific conferences, research seminars and invited presentations.